IDH1 and central nervous system cancer: In this context, mutations in the active site of isocitrate dehydrogenase 1 (IDH1), a catalytic enzyme that produces alpha-ketoglutarate (α-KG) by oxidative decarboxylation of isocitrate [8], have been related to a better prognosis in glioma patients.